NuCana plc stock is up 17.1% since 30 days ago. The next earnings date is Apr 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
NuCana plc engages in the development of products for the treatment of cancer. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil.